Sope Olugbile, MD
Medical Oncology · Atlanta, GANPI 1427344175
Payments from drug & device makers
What this record shows
Almost everything reported here is food and beverage — 94.9% of the total across 99 separate payments, which is the pattern of a clinician who attends manufacturer presentations rather than one with a consulting arrangement. It is spread thinly across 37 manufacturers, the largest accounting for just 15.3% — the pattern of someone who eats at a lot of different presentations. 2025 is the largest year on record at $2,166, more than ten times the $23 reported in 2020. That places this record below the midpoint for medical oncology clinicians in GA, where the typical reported total is $5,509.
Across 99 payments — averaging $23.97 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- AstraZeneca$363
- Johnson & Johnson$285
- Pfizer$269
- Eisai Inc.$141
- GSK$127
- Daiichi Sankyo Inc.$118
- plus $1K from 31 others
Across 14 payments — averaging $13,879 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.
- Merck$120K
- Janssen Research & Development, LLC$74K
What the payments were for
- Food & beverage$2,25195%
- Education$1225%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| AstraZeneca(2 entities) | 10 | $363 |
| Johnson & Johnson(3 entities) | 7 | $285 |
| Pfizer | 15 | $269 |
| Eisai Inc. | 7 | $141 |
| GSK | 6 | $127 |
| Daiichi Sankyo Inc. | 6 | $118 |
| Merck | 5 | $108 |
| Fujifilm Healthcare Americas Corporation | 1 | $86 |
| Bayer | 3 | $78 |
| EMD Serono, Inc. | 2 | $60 |
| Astellas Pharma US Inc | 2 | $55 |
| Karyopharm Therapeutics Inc. | 2 | $47 |
| Genentech USA, Inc. | 2 | $40 |
| Array Biopharma Inc | 6 | $38 |
| Sanofi | 2 | $36 |
| Takeda Pharmaceuticals U.S.A., Inc. | 1 | $33 |
| Taiho Oncology, Inc. | 1 | $31 |
| Springworks Therapeutics, Inc. | 2 | $31 |
| Tempus AI, Inc | 1 | $29 |
| Boehringer Ingelheim | 1 | $29 |
| Iovance Biotherapeutics, Inc. | 1 | $26 |
| Beone Medicines USA, Inc. | 1 | $25 |
| Caris MPI, Inc. | 1 | $25 |
| Exelixis Inc. | 1 | $25 |
| Fennec Pharmaceuticals, Inc. | 1 | $25 |
| Coherus Oncology, Inc. | 1 | $24 |
| Regeneron Healthcare Solutions, Inc. | 1 | $24 |
| Gilead | 1 | $24 |
| Adaptive Biotechnologies Corporation | 1 | $22 |
| Sun Pharmaceutical Industries Inc. | 1 | $22 |
| Novartis | 1 | $22 |
| Legend Biotech USA Inc. | 1 | $21 |
| Agios Pharmaceuticals, Inc. | 1 | $20 |
| Incyte Corporation | 1 | $20 |
| Sumitomo Pharma America, Inc. | 1 | $18 |
| AbbVie | 1 | $16 |
| Pharmaand GmbH | 1 | $11 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- RYBREVANT$141
How this compares
$2,373 in reported general payments places this provider in the 30th percentile of 68 medical oncology providers in Georgia.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| TagrissoOsimertinib Mesylate | 47 | $778,629 |
| CalquenceAcalabrutinib Maleate | 40 | $550,515 |
| Abiraterone Acetate | 192 | $253,714 |
| TabrectaCapmatinib Hydrochloride | 17 | $223,718 |
| ImbruvicaIbrutinib | 11 | $179,144 |
| EliquisApixaban | 70 | $77,450 |
| Gammagard LiquidImmun Glob G(Igg)/Gly/Iga Ov50 | 13 | $76,290 |
| XareltoRivaroxaban | 58 | $74,972 |
| CreonLipase/Protease/Amylase | 16 | $18,984 |
| Enoxaparin Sodium | 16 | $11,981 |
| Dabigatran EtexilateDabigatran Etexilate Mesylate | 13 | $4,770 |
| Mirtazapine | 39 | $1,179 |
| Ondansetron OdtOndansetron | 58 | $985 |
| Hydroxyurea | 23 | $773 |
| Prednisone | 165 | $740 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| AstraZenecaTagrisso, Calquence | $363 | $1,329,14387 claims |
| NovartisTabrecta | $22 | $223,71817 claims |
| PfizerEliquis | $269 | $77,45070 claims |
| Takeda Pharmaceuticals U.S.A., Inc.Gammagard Liquid | $33 | $76,29013 claims |
| Johnson & JohnsonXarelto | $285 | $74,97258 claims |
| AbbVieCreon | $16 | $18,98416 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 30th percentile of 68 medical oncology providers in Georgia.
Other medical oncology in Atlanta
- Nabil SabaAtlanta$225K
- Suresh RamalingamAtlanta$75K
- Jonathan KaufmanAtlanta$73K
- Ragini KudchadkarAtlanta$69K
- Nisha JosephAtlanta$50K
- Eyal MeiriAtlanta$39K
- Erin DunbarAtlanta$35K
- Olumide GbolahanAtlanta$32K
- Bradley CarthonAtlanta$31K
- Joseph MaakaronAtlanta$29K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.